What we know
Head and neck cancers take many forms, and can occur in the mouth, throat, salivary glands, nose and the middle ear.
In most types of cancer, metastasis (cancer that spreads to a different part of the body from where it started – the primary site) is the most frequent cause of death. Head and neck cancers, however, work differently. In these cases, the disease and death are largely the result of one of two factors: a spread of the cancerous cells, or a recurrence of the disease after treatment. As a result, treatments such as chemotherapy or radiotherapy often don’t work.
Or study involves using immunotherapy which boosts and helps the body’s own natural defences to fight cancer. Immunotherapy is a rapidly growing form of cancer treatments and we hope to use it to offer new treatment for those with head and neck cancers.
30% – the increase in cases of head and neck cancer in the UK since the early 1990s
11,449 new cases of head and neck cancer in 2014
Between 19% and 59% of patients with a form of head and neck cancer that survive their disease for ten years or more.
What we are doing
We will take a blood sample from our patients and then treat the white blood cells with a harmless virus to create two new genes. The first stimulates growth of white blood cells, and the second helps these cells to recognise and attack the cancerous growth (tumour). After two weeks, a CAR-T cell is created, which supports the body’s own immune system to target head and neck cancers. The CAR-T cell is then injected directly into the patient to fight the disease.
CAR-T Cell Therapy has been used to successfully treat some forms of leukaemia, but more research is needed for treatment of “solid cancers”.
The aim of this study is to determine:
- How well the treatment works
- The best and safest dosage
- How the body responds to it.
What we hope to find
“If this trial is successful, it could have significant implications for other solid cancers, especially those that spread within a natural space in the body, such as ovarian cancer.”
Dr John Maher, Principal Investigator at the NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
About the study
Find out more